# FDA recall D-1058-2017

> **Teva Pharmaceuticals USA** · Class III · drug recall initiated 2017-08-02.

## Product

Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15

## Reason for recall

Failed Moisture Limits: out of specification test results for water content obtained during stability testing.

## Distribution

Product distributed to OH, IL, PA, MI, VA and CT

## Key facts

- **Recall number:** D-1058-2017
- **Recalling firm:** Teva Pharmaceuticals USA
- **Classification:** Class III
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2017-08-02
- **Report date:** 2017-08-16
- **Termination date:** 2018-02-28

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** North Wales, PA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1058-2017

## Citation

> AI Analytics. FDA recall D-1058-2017. Retrieved 2026-06-05 from https://api.ai-analytics.org/recall/D-1058-2017. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*